REQUIREMENTS CHECKLIST FOR DRUG INFORMATION RESPONSE¹

Note: Student expectations for this activity to commensurate with expected year level performance characteristics

NA = Not Applicable; U = Unsatisfactory; S = Satisfactory

Student Name:

QUESTION:		
NA U S		
☐ ☐ ☐ Clearly documents and articulates the drug information question.		
□ □ Selects a drug information question that is patient-care focused and patient-specific.		
and a selected a drag information question that is patient care rocased and patient specime.		
BACKGROUND INFORMATION AND PATIENT ASSESSMENT:		
NA U S		
Provides the general context from which the question arises and provides the background		
information necessary to understand the question being asked.		
Provides the background information necessary to understand the patient, as appropriate:		
Pertinent patient information (e.g. age, gender, weight, allergy assessment, body mass index, current diet and exercise,		
etc.)		
 Subjective and objective data, including relevant laboratory values, physical signs and symptoms 		
Family and social history		
Patient's beliefs/concerns and goals for health and wellness		
List complete past and current medical condition/associated conditions		
 List complete past and current medication therapies (prescription and non-prescription), including generic name, 		
indication, doses, frequency, duration, etc.		
☐ ☐ ☐ Uses supporting data (laboratory data, physical signs and symptoms, test results, etc) to		
support assessment of patient		
RESEARCH AND RESPONSE:		
NA U S		
☐ ☐ Provides a comprehensive, organized, timely response to the question [usual length is two to four pages (not including		
references		
list), depending on complexity of the question].		
□ □ Presents information in an organized and logical manner. Answer is concise and does not unnecessarily repeat		
information.		
Describes the search strategy (primary or tertiary literature, databases used, search terms used, etc) and resources (online		
tertiary references, guidelines, etc) used to find information to answer the question.		
Answers the specific question and fully discusses the thought process (N,E,S,A) relevant to the drug(s) and medical condition involved (e.g. Necessary – include pathophysiology, signs/symptoms, causes, drug and nondrug risk factors etc.)		
unless		
otherwise directed		
□ □ Conducts critical appraisal and evaluation of the evidence.		
Accesses and evaluates the full publication of any evidence if possible (does not use only the abstract to draw conclusions)		
Considers the purpose, intervention, methodology of any clinical trials used to answer the question		
Clearly represents the results of any evidence found		
Considers the strengths and weaknesses of the trial / evidence		
Applies the clinical literature to the patient; identifies limitations of applicability		
□ □ Provides clear and detailed recommendation(s) and rationale for decision-making. Final recommendations include:		
 Concise dosing recommendations (drug, dose, route of administration, regimen, frequency, and duration) that are patient 		
specific and supported with appropriate references		
 Pharmacokinetic dosing and drug monitoring, where appropriate. Incorporate dosage adjustment into the therapeutic plan for 		
patient, where appropriate		
 Tapering/titration schedules, where applicable, that are clearly articulated 		
 Rationale and evidence for ALL recommendations (drug and non-drug) 		
 Patient preferences/values (e.g. once daily versus twice daily dosing) 		
 Non-drug measures that are relevant and patient specific 		
 Adverse drug reaction (ADR) profile of drug option(s) and medication administration 		
 Viable therapeutic alternatives are discussed and rationale for choice is provided. Provide reasoning (compare and contrast 		
Efficacy, Safety and Adherence) for alternatives for your specific patient.		
Address patient's unmet needs.		
☐ ☐ Summarizes the finding and recommendation(s) into a clear final conclusion or summary paragraph		

MONITORING PLAN AND OUTCOME:	
NA U	States relevant monitoring endpoints, including Effectiveness and Safety endpoints, appropriate frequency, duration, expected change, date, and who is responsible for monitoring and follow up.
	O France Production of Product
REFERENCES:	
NA U	Provides complete citation list using Vancouver style for written submissions. Uses primary literature and other resources appropriately to address the question.
COMMENTS:	
OVERAL	L ASSESSMENT: ☐ Unsatisfactory ☐ Satisfactory

¹Adapted with permission: Drug Information Form, BC Drug and Poison Information Centre, Vancouver British Columbia 2012.